Merck, Eisai Announce Interim Data Investigating Keytruda, Halaven Combination

Merck Inc. (MRK) and Eisai Inc. (ESALY.PK) today announced new interim data investigating Merck's anti-PD-1 therapy, Keytruda or pembrolizumab, in combination with Eisai's microtubule dynamics inhibitor, Halaven or eribulin, in patients with metastatic triple-negative breast cancer (TNBC).

from RTT - Biotech http://ift.tt/2hoLrEG
via IFTTT